Tenofovir-Diphosphate and Emtricitabine-Triphosphate Adherence Benchmarks in Dried Blood Spots for Persons With HIV Receiving Tenofovir Alafenamide and Emtricitabine–Based Antiretroviral Therapy (QUANTI-TAF)

• Published in: Clinical infectious diseases 2024-11, Vol.79 (5), p.1233-1241
• Main Authors: Coyle, Ryan P, Morrow, Mary, Mann, Sarah C, Mainella, Vincent, Ellis, Samuel L, Schwab, Stefanie, Coppinger, Corwin, Barker, Nicholas, Ellison, Lucas, Zheng, Jia-Hua, Al Zuabi, Subhi, Alpert, Pamela E, Carnes, Tony C, Buffkin, D Eric, Chai, Peter R, Bushman, Lane R, Kiser, Jennifer J, MaWhinney, Samantha, Brooks, Kristina M, Anderson, Peter L, Castillo-Mancilla, Jose R
• Format: Article
• Language: English
• Subjects: Adenine - administration & dosage; Adenine - analogs & derivatives; Adenine - pharmacokinetics; Adenine - therapeutic use; Adult; Alanine - administration & dosage; Alanine - analogs & derivatives; Alanine - pharmacokinetics; Alanine - therapeutic use; Anti-HIV Agents - administration & dosage; Anti-HIV Agents - pharmacokinetics; Anti-HIV Agents - therapeutic use; Benchmarking; Dried Blood Spot Testing - methods; Emtricitabine - administration & dosage; Emtricitabine - pharmacokinetics; Emtricitabine - therapeutic use; Female; HIV Infections - drug therapy; Humans; Male; Medication Adherence - statistics & numerical data; Middle Aged; Organophosphates - administration & dosage; Organophosphates - blood; Organophosphates - pharmacokinetics; Organophosphates - therapeutic use
• ISSN: 1058-4838; 1537-6591; 1537-6591
• DOI: 10.1093/cid/ciae212

Abstract Background QUANTI-TAF aimed to establish tenofovir-diphosphate (TFV-DP)/emtricitabine-triphosphate (FTC-TP) adherence benchmarks in dried blood spots (DBS) for persons with human immunodeficiency virus (PWH) receiving tenofovir alafenamide/emtricitabine (TAF/FTC)–based antiretroviral therapy (ART). Methods For 16 weeks, PWH received TAF/FTC-based ART co-encapsulated with an ingestible sensor to directly measure cumulative (enrollment to final visit) and 10-day adherence. At monthly visits, intraerythrocytic concentrations of TFV-DP and FTC-TP in DBS were quantified and summarized at steady-state (week 12 or 16) as median (interquartile range). Linear mixed-effects models evaluated factors associated with TFV-DP/FTC-TP. Results Eighty-four participants (11% female, 4% transgender) predominantly receiving bictegravir/TAF/FTC (73%) were enrolled. Ninety-two percent completed week 12 or 16 (94% unboosted ART). TFV-DP for